Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion

NCT00422201 is registered in ClinicalTrials.gov with HRA Pharma as lead sponsor.

NCT NCT00422201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00422201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion
Lead sponsor
HRA Pharma
Phase
Phase 2
Overall status
Terminated
Start date
May 15, 2007
Completion date
April 4, 2012
Enrollment
18 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

cushing's syndrome